CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Kane Biotech Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Kane Biotech Inc
290-100 Innovation Drive
Phone: (204) 453-1301p:204 453-1301 WINNIPEG, MB  R3T 6G2  Canada Ticker: KNEKNE
Business Summary
Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (65 patents and patents pending as well as trade secrets and trademarks) and products developed by Kane's own biofilm research and acquired from research institutions. DispersinB, coactiv+, DermaKB, DermaKB Biofilm, and revyve are trademarks of Kane Biotech Inc. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. The Company's other biofilm disruption technology is DispersinB. DispersinB is a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG). DispersinB cleaves PNAG, inhibiting bacterial adhesion and disperses the biofilm.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
6794 Patent owners and lessors

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board PhilipRenaud 1/1/2022 9/15/2010
President, Chief Executive Officer, Director MarcEdwards 9/10/2018 2/6/2016
Chief Financial Officer Raymond D.Dupuis 9/5/2017 9/5/2017
6 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 137,511,567 (As of 9/30/2024)
Stock Exchange: CVE
Fax Number: (204) 474-7552
Email Address: info@kanebiotech.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025